189:@0.890196:0.957873:0.914828:0.957873:0.914828:0.938882:0.890196:0.938882:0.007450:0.008591:0.008591
REFERENCES:@0.789358:0.066557:0.882352:0.066557:0.882352:0.045634:0.789358:0.045634:0.010295:0.008537:0.008058:0.008537:0.010295:0.008537:0.010706:0.010089:0.008398:0.009542
viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain :@0.184412:0.119718:0.886126:0.119718:0.886126:0.101197:0.184412:0.101197:0.008944:0.005105:0.007242:0.010376:0.007159:0.008218:0.006973:0.004088:0.004296:0.006599:0.010438:0.004088:0.004296:0.012762:0.005105:0.007180:0.008550:0.004773:0.004296:0.015709:0.010500:0.004462:0.005852:0.004794:0.010148:0.004773:0.005043:0.008280:0.008010:0.005852:0.005043:0.009857:0.010687:0.004296:0.005105:0.010687:0.004296:0.008446:0.004296:0.006827:0.005956:0.008280:0.009919:0.004711:0.008218:0.004296:0.006827:0.005852:0.007180:0.008259:0.005105:0.010687:0.004296:0.009857:0.005644:0.004296:0.010085:0.010376:0.015979:0.008259:0.010687:0.004296:0.015979:0.008550:0.004773:0.005105:0.008965:0.010625:0.008259:0.010355:0.005852:0.004296:0.008301:0.010065:0.004794:0.006018:0.010272:0.008135:0.004773:0.005271:0.008548:0.004773:0.004296:0.008176:0.008135:0.004897:0.004773:0.006973:0.004296:0.006308:0.006827:0.005852:0.007180:0.008259:0.005105:0.010687:0.003735
HeLa) derived from an epidermoid carcinoma of the cervix. J. Exp. Med. 97, 695–710 (1953).:@0.184412:0.140297:0.882353:0.140297:0.882353:0.121776:0.184412:0.121776:0.014734:0.008218:0.010895:0.008446:0.006308:0.003059:0.010293:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.003061:0.005829:0.006765:0.009859:0.016041:0.003059:0.008259:0.010687:0.003061:0.008301:0.010065:0.005043:0.010293:0.008218:0.007097:0.015896:0.009857:0.005043:0.010355:0.003059:0.008280:0.008259:0.006765:0.008176:0.005105:0.010542:0.009857:0.015979:0.008446:0.003061:0.009857:0.005644:0.003061:0.006016:0.010274:0.008218:0.003059:0.008176:0.008218:0.007637:0.008944:0.005105:0.009172:0.004088:0.003059:0.005105:0.004088:0.003061:0.011061:0.009172:0.009544:0.004088:0.003061:0.017245:0.008280:0.010106:0.004088:0.003059:0.009483:0.009483:0.004088:0.003061:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003057:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
93.  Beskow, L. M. Lessons from HeLa Cells: The Ethics and Policy of Biospecimens. Annu. Rev. :@0.147059:0.160875:0.886043:0.160875:0.886043:0.142355:0.147059:0.142355:0.009483:0.009483:0.004088:0.003735:0.010563:0.011891:0.008218:0.006869:0.009338:0.009878:0.011808:0.004088:0.003964:0.010563:0.004088:0.003964:0.017826:0.004088:0.003964:0.010747:0.008218:0.006848:0.007159:0.009857:0.010563:0.006973:0.003964:0.005831:0.006765:0.009857:0.016041:0.003964:0.014734:0.008218:0.010895:0.008446:0.003964:0.013632:0.008135:0.004897:0.004773:0.006973:0.004088:0.003964:0.010428:0.010282:0.008218:0.003964:0.010461:0.006016:0.010417:0.005045:0.008176:0.006973:0.003964:0.008259:0.010542:0.010355:0.003964:0.010148:0.009940:0.004773:0.005043:0.008529:0.008840:0.003964:0.009857:0.005644:0.003964:0.011351:0.005043:0.009961:0.006827:0.010459:0.008280:0.008176:0.005105:0.015896:0.008218:0.010563:0.006973:0.004088:0.003964:0.013572:0.010687:0.010355:0.010127:0.004088:0.003964:0.012451:0.008485:0.007369:0.004088:0.003735
Genomics Hum. Genet. 17, 395–417 (2016).:@0.184412:0.181454:0.523929:0.181454:0.523929:0.162933:0.184412:0.162933:0.014381:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.006973:0.003735:0.014402:0.010376:0.016041:0.004088:0.003735:0.014381:0.008218:0.010542:0.008301:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
94.  Masters, J. R. HeLa cells 50 years on: the good, the bad and the ugly. Nat. Rev. Cancer 2, :@0.147059:0.202033:0.886086:0.202033:0.886086:0.183512:0.147059:0.183512:0.009483:0.009483:0.004088:0.003735:0.010563:0.017348:0.008446:0.006827:0.005644:0.008218:0.006931:0.006973:0.004088:0.005842:0.005105:0.004088:0.005842:0.012451:0.004088:0.005842:0.014734:0.008218:0.010895:0.008446:0.005842:0.008176:0.008135:0.004897:0.004773:0.006973:0.005842:0.009483:0.009483:0.005842:0.008653:0.008444:0.008261:0.006931:0.006973:0.005842:0.009857:0.010687:0.004088:0.005842:0.006018:0.010272:0.008218:0.005842:0.008778:0.010251:0.010251:0.010106:0.004088:0.005842:0.006018:0.010272:0.008218:0.005842:0.010106:0.008446:0.010355:0.005842:0.008259:0.010542:0.010355:0.005842:0.006018:0.010272:0.008218:0.005842:0.010376:0.009027:0.004711:0.007263:0.004088:0.005842:0.014132:0.008010:0.005852:0.004088:0.005842:0.012451:0.008487:0.007367:0.004088:0.005842:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.005842:0.009483:0.004088:0.003735
315–319 (2002).:@0.184412:0.222612:0.310415:0.222612:0.310415:0.204091:0.184412:0.204091:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
95.  Skloot, R. The Immortal Life of Henrietta Lacks. (Pan Publishing, 2011).:@0.147059:0.243190:0.733016:0.243190:0.733016:0.224669:0.147059:0.224669:0.009483:0.009483:0.004088:0.003735:0.010563:0.008923:0.009899:0.004711:0.010251:0.009836:0.005852:0.004088:0.003735:0.012451:0.004088:0.003735:0.010428:0.010280:0.008218:0.003735:0.006267:0.016041:0.015896:0.009857:0.007242:0.005956:0.008550:0.004773:0.003735:0.010666:0.005105:0.005476:0.008218:0.003735:0.009857:0.005644:0.003735:0.014734:0.008218:0.010687:0.007097:0.005043:0.008301:0.005603:0.005956:0.008446:0.003735:0.010895:0.008446:0.007969:0.009566:0.006973:0.004088:0.003735:0.006308:0.010374:0.008259:0.010687:0.003735:0.010895:0.010314:0.009919:0.004773:0.005105:0.006869:0.010417:0.005105:0.010417:0.008799:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
96.  Kamb, A. What’s wrong with our cancer models? Nat. Rev. Drug Discov. 4, 161–165 (2005).:@0.147059:0.263769:0.878362:0.263769:0.878362:0.245248:0.147059:0.245248:0.009483:0.009483:0.004088:0.003735:0.010563:0.012866:0.008259:0.015813:0.009317:0.004088:0.003735:0.013572:0.004088:0.003735:0.018822:0.010355:0.008010:0.004960:0.001577:0.006973:0.003735:0.013385:0.006765:0.009857:0.010417:0.008965:0.003735:0.013385:0.004792:0.006018:0.010417:0.003735:0.009836:0.010376:0.007097:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.015896:0.010251:0.010293:0.008135:0.004773:0.006973:0.006952:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.012451:0.008485:0.007367:0.004088:0.003735:0.014568:0.007242:0.010376:0.008965:0.003735:0.014568:0.005105:0.007157:0.008176:0.009878:0.007369:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
97.  Barretina, J. :@0.147059:0.284348:0.278354:0.284348:0.278354:0.265827:0.147059:0.265827:0.009483:0.009483:0.004088:0.003735:0.010563:0.011704:0.008259:0.007097:0.006765:0.008301:0.005852:0.005105:0.010625:0.008446:0.004088:0.004773:0.005105:0.004088:0.003735
et al.:@0.279382:0.284348:0.315573:0.284348:0.315573:0.265636:0.279382:0.265636:0.007346:0.005727:0.004877:0.009048:0.004607:0.004586
 The Cancer Cell Line Encyclopedia enables predictive modelling of anti-:@0.315570:0.284348:0.882353:0.284348:0.882353:0.265827:0.315570:0.265827:0.004773:0.010428:0.010282:0.008218:0.004773:0.013611:0.008259:0.010544:0.008176:0.008218:0.007097:0.004773:0.013634:0.008135:0.004897:0.004773:0.004773:0.010666:0.005105:0.010542:0.008218:0.004773:0.010998:0.010544:0.008527:0.008653:0.007971:0.004711:0.009836:0.010457:0.008280:0.010355:0.005271:0.008446:0.004773:0.008218:0.010625:0.008280:0.009919:0.004711:0.008218:0.006973:0.004773:0.010065:0.006765:0.008280:0.010355:0.005043:0.008278:0.005852:0.005043:0.008759:0.008218:0.004773:0.015896:0.010251:0.010293:0.008135:0.004897:0.004773:0.005105:0.010417:0.008965:0.004773:0.009857:0.005644:0.004773:0.008259:0.010355:0.005852:0.005057:0.006848
cancer drug sensitivity. Nature 483, 603–607 (2012).:@0.184412:0.304926:0.581720:0.304926:0.581720:0.286406:0.184412:0.286406:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.010355:0.007242:0.010376:0.008965:0.003735:0.007157:0.008218:0.010563:0.006910:0.004794:0.005852:0.005043:0.008944:0.004794:0.005852:0.007263:0.004088:0.003735:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
98.  Verschraegen, C. F. :@0.147059:0.325505:0.331561:0.325505:0.331561:0.306984:0.147059:0.306984:0.009483:0.009483:0.004088:0.003735:0.010563:0.011579:0.008218:0.006931:0.007159:0.007969:0.010417:0.007180:0.008446:0.008218:0.008778:0.008218:0.010687:0.004088:0.003050:0.013343:0.004088:0.003050:0.007906:0.004088:0.003735
et al.:@0.330856:0.325505:0.365283:0.325505:0.365283:0.306793:0.330856:0.306793:0.007346:0.005727:0.003113:0.009048:0.004607:0.004586
 Establishment and characterization of cancer cell cultures and xeno-:@0.365281:0.325505:0.882353:0.325505:0.882353:0.306984:0.365281:0.306984:0.003050:0.010998:0.006827:0.005956:0.008280:0.009919:0.004773:0.005105:0.006869:0.010417:0.015896:0.008218:0.010355:0.005852:0.003050:0.008259:0.010542:0.010355:0.003050:0.007969:0.010355:0.008259:0.007180:0.008446:0.008280:0.005644:0.008218:0.007097:0.005105:0.008031:0.008010:0.005852:0.005043:0.009857:0.010687:0.003050:0.009857:0.005644:0.003050:0.008278:0.008261:0.010542:0.008176:0.008218:0.007097:0.003050:0.008176:0.008137:0.004895:0.004773:0.003050:0.008280:0.010500:0.004462:0.005603:0.010376:0.006765:0.008218:0.006973:0.003050:0.008259:0.010542:0.010355:0.003050:0.008985:0.008218:0.010542:0.009985:0.006848
grafts derived from primary or metastatic Mullerian cancers. Clin. Cancer Res. 9, 845–852 :@0.184412:0.346084:0.886124:0.346084:0.886124:0.327563:0.184412:0.327563:0.008965:0.007180:0.008259:0.005634:0.005634:0.006973:0.004617:0.010293:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.004617:0.005831:0.006765:0.009857:0.016041:0.004628:0.010062:0.007097:0.005105:0.015979:0.008261:0.007635:0.008840:0.004628:0.009857:0.007097:0.004617:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.004617:0.016954:0.010500:0.004897:0.004711:0.008218:0.007097:0.005271:0.008259:0.010687:0.004617:0.008280:0.008259:0.010542:0.008176:0.008218:0.006931:0.006973:0.004088:0.004628:0.013403:0.004773:0.005105:0.010687:0.004088:0.004617:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.004617:0.012451:0.008218:0.006973:0.004088:0.004628:0.009483:0.004088:0.004617:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735
(2003).:@0.184412:0.366663:0.239051:0.366663:0.239051:0.348142:0.184412:0.348142:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
99.  Ince, T. A. :@0.147059:0.387241:0.267750:0.387241:0.267750:0.368720:0.147059:0.368720:0.009483:0.009483:0.004088:0.003735:0.010563:0.006267:0.010542:0.008176:0.007948:0.004088:0.005437:0.009961:0.004088:0.005437:0.013572:0.004088:0.003735
et al.:@0.269439:0.387241:0.306315:0.387241:0.306315:0.368529:0.269439:0.368529:0.007346:0.005727:0.005561:0.009048:0.004607:0.004586
 Characterization of twenty-five ovarian tumour cell lines that phenocopy :@0.306306:0.387241:0.886129:0.387241:0.886129:0.368720:0.306306:0.368720:0.005437:0.013406:0.010355:0.008259:0.007180:0.008446:0.008280:0.005644:0.008218:0.007097:0.005105:0.008031:0.008010:0.005852:0.005043:0.009857:0.010687:0.005437:0.009857:0.005644:0.005437:0.005852:0.013198:0.008218:0.010357:0.005852:0.008840:0.006848:0.005167:0.005103:0.008757:0.008218:0.005437:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005437:0.005603:0.010376:0.015898:0.009836:0.010376:0.007097:0.005437:0.008176:0.008135:0.004897:0.004773:0.005437:0.004773:0.005105:0.010542:0.008218:0.006973:0.005437:0.006018:0.010355:0.008010:0.005852:0.005437:0.010148:0.010272:0.008218:0.010542:0.010251:0.008176:0.009836:0.010085:0.008840:0.003735
primary tumours. Nat. Commun. 6, 7419 (2015).:@0.184412:0.407820:0.558499:0.407820:0.558499:0.389299:0.184412:0.389299:0.010065:0.007097:0.005105:0.015979:0.008259:0.007637:0.008840:0.003735:0.005603:0.010376:0.015896:0.009836:0.010376:0.006931:0.006973:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.013632:0.009857:0.016041:0.015709:0.010376:0.010687:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
100. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour :@0.147059:0.428399:0.886126:0.428399:0.886126:0.409878:0.147059:0.409878:0.009483:0.009483:0.009483:0.004088:0.004814:0.014754:0.009857:0.015896:0.007969:0.009338:0.007948:0.004088:0.003839:0.009193:0.004088:0.004088:0.003839:0.009193:0.005105:0.010789:0.010355:0.008446:0.004088:0.003839:0.012451:0.004088:0.004088:0.003839:0.010749:0.008487:0.008944:0.005105:0.010540:0.007950:0.004088:0.003839:0.013738:0.004088:0.003839:0.013572:0.004088:0.004088:0.003839:0.009193:0.008259:0.010542:0.010293:0.008218:0.005686:0.004088:0.003839:0.013343:0.004088:0.003839:0.014298:0.003839:0.009629:0.007969:0.010085:0.010500:0.004462:0.005914:0.008031:0.004088:0.003839:0.014754:0.004088:0.003839:0.010729:0.008944:0.008550:0.004462:0.010542:0.008010:0.005852:0.005105:0.010417:0.008965:0.003839:0.008176:0.008137:0.004895:0.004773:0.003839:0.004773:0.005105:0.010542:0.008218:0.006973:0.003839:0.008446:0.006973:0.003839:0.005603:0.010376:0.015896:0.009836:0.010376:0.007097:0.003735
models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).:@0.184412:0.448977:0.750929:0.448977:0.750929:0.430456:0.184412:0.430456:0.015896:0.010251:0.010293:0.008135:0.004773:0.006973:0.003735:0.009857:0.008840:0.003735:0.008176:0.009857:0.015709:0.010334:0.008259:0.007097:0.005105:0.007157:0.009857:0.010687:0.003735:0.009857:0.005644:0.003735:0.008778:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.003735:0.010065:0.006765:0.009857:0.005167:0.005292:0.004711:0.008218:0.006973:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.013634:0.009857:0.016041:0.015709:0.010376:0.010687:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
101. Ben-David, U. :@0.147059:0.469556:0.299685:0.469556:0.299685:0.451035:0.147059:0.451035:0.009483:0.009483:0.009483:0.004088:0.004814:0.011891:0.008218:0.010687:0.006848:0.014732:0.008116:0.008944:0.005041:0.010106:0.004088:0.006142:0.012638:0.004088:0.003735
et al.:@0.302073:0.469556:0.339654:0.469556:0.339654:0.450844:0.302073:0.450844:0.007346:0.005727:0.006267:0.009048:0.004607:0.004586
 Genetic and transcriptional evolution alters cancer cell line drug re-:@0.339655:0.469556:0.882353:0.469556:0.882353:0.451035:0.339655:0.451035:0.006132:0.014381:0.008218:0.010542:0.008301:0.005852:0.005043:0.008176:0.006132:0.008259:0.010544:0.010355:0.006132:0.005852:0.007180:0.008259:0.010563:0.007159:0.008176:0.007097:0.004792:0.010044:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.006132:0.008487:0.008757:0.009940:0.004462:0.010065:0.005852:0.005043:0.009857:0.010687:0.006142:0.008548:0.004462:0.005647:0.008218:0.006929:0.006973:0.006142:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.006132:0.008176:0.008135:0.004897:0.004773:0.006132:0.004773:0.005105:0.010542:0.008218:0.006132:0.010355:0.007242:0.010376:0.008965:0.006132:0.006765:0.008200:0.006848
sponse. Nature 560, 325–330 (2018).:@0.184412:0.490135:0.464164:0.490135:0.464164:0.471614:0.184412:0.471614:0.006827:0.010459:0.009857:0.010563:0.007159:0.007948:0.004088:0.003735:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
102. Tentler, J. J. :@0.147059:0.510713:0.273332:0.510713:0.273332:0.492193:0.147059:0.492193:0.009483:0.009483:0.009483:0.004088:0.004814:0.009878:0.008218:0.010355:0.006018:0.004711:0.008218:0.005686:0.004088:0.004814:0.005105:0.004088:0.004814:0.005105:0.004088:0.003735
et al.:@0.274421:0.510713:0.310653:0.510713:0.310653:0.492001:0.274421:0.492001:0.007346:0.005727:0.004918:0.009048:0.004607:0.004586
 Patient-derived tumour xenografts as models for oncology drug develop-:@0.310659:0.510713:0.882353:0.510713:0.882353:0.492193:0.310659:0.492193:0.004814:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005041:0.008759:0.008278:0.010355:0.004814:0.005603:0.010376:0.015896:0.009836:0.010376:0.007097:0.004814:0.008985:0.008218:0.010544:0.010044:0.008965:0.007178:0.008259:0.005634:0.005634:0.006973:0.004814:0.008446:0.006973:0.004814:0.015896:0.010249:0.010295:0.008135:0.004773:0.006973:0.004814:0.005478:0.009857:0.007097:0.004814:0.009857:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.008840:0.004814:0.010355:0.007242:0.010376:0.008965:0.004814:0.010291:0.008487:0.008757:0.008135:0.004711:0.009836:0.010283:0.006848
ment. Nat. Rev. Clin. Oncol. 9, 338–350 (2012).:@0.184412:0.531292:0.545426:0.531292:0.545426:0.512771:0.184412:0.512771:0.015896:0.008218:0.010355:0.005852:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.012451:0.008487:0.007367:0.004088:0.003735:0.013403:0.004773:0.005105:0.010687:0.004088:0.003735:0.014817:0.010542:0.008176:0.009940:0.004524:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
103. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654–:@0.147059:0.551871:0.882368:0.551871:0.882368:0.533350:0.147059:0.533350:0.009483:0.009483:0.009483:0.004088:0.004814:0.009774:0.006765:0.008218:0.007159:0.007948:0.004088:0.004752:0.013219:0.004088:0.004752:0.013219:0.004088:0.004752:0.014298:0.004752:0.009919:0.010314:0.008757:0.008218:0.007159:0.009857:0.010687:0.004088:0.004752:0.013735:0.004088:0.004752:0.013572:0.004088:0.004752:0.017348:0.008446:0.009172:0.005105:0.016041:0.005105:0.008031:0.005105:0.010417:0.008965:0.004752:0.015898:0.009836:0.010376:0.007157:0.008218:0.004752:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.004752:0.015896:0.010249:0.010295:0.008135:0.004773:0.006973:0.004088:0.004752:0.014132:0.008010:0.005852:0.004088:0.004752:0.012449:0.008487:0.007367:0.004088:0.004752:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.004752:0.009483:0.004088:0.004752:0.009483:0.009483:0.009483:0.010729
658 (2007).:@0.184412:0.572450:0.271236:0.572450:0.271236:0.553929:0.184412:0.553929:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
104. Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples :@0.147059:0.593028:0.886020:0.593028:0.886020:0.574507:0.147059:0.574507:0.009483:0.009483:0.009483:0.004088:0.004814:0.009193:0.005043:0.009940:0.004939:0.008446:0.006973:0.004088:0.004607:0.013738:0.004088:0.004607:0.014298:0.004607:0.014713:0.008259:0.010687:0.010542:0.009857:0.010687:0.004088:0.004607:0.014256:0.004088:0.004607:0.005105:0.004088:0.004607:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005041:0.008757:0.008280:0.010355:0.004607:0.005603:0.010376:0.015896:0.009857:0.007097:0.004607:0.008985:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.006973:0.004088:0.004607:0.005852:0.007180:0.008259:0.010563:0.006910:0.005478:0.009857:0.007097:0.016041:0.005105:0.010417:0.008965:0.004607:0.007969:0.004773:0.005105:0.010687:0.005041:0.008280:0.008550:0.004773:0.004607:0.007222:0.008259:0.015709:0.010148:0.004711:0.008218:0.006973:0.003735
into mouse models. Cancer Res. 73, 5315–5319 (2013).:@0.184412:0.613607:0.605522:0.613607:0.605522:0.595086:0.184412:0.595086:0.005105:0.010355:0.005644:0.010044:0.003735:0.015896:0.009836:0.010376:0.007159:0.008218:0.003735:0.015896:0.010251:0.010293:0.008135:0.004773:0.006973:0.004088:0.003735:0.013611:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.006973:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
105. Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft :@0.147059:0.634186:0.883380:0.634186:0.883380:0.615665:0.147059:0.615665:0.009483:0.009483:0.009483:0.004088:0.004814:0.012721:0.010334:0.008259:0.007097:0.005043:0.008176:0.005043:0.009338:0.004088:0.005188:0.009193:0.004088:0.004088:0.005188:0.014983:0.005043:0.010521:0.008548:0.004773:0.008778:0.009338:0.004088:0.005188:0.017826:0.004088:0.005188:0.014298:0.005188:0.012409:0.010376:0.010417:0.008799:0.004088:0.005188:0.013572:0.004088:0.005188:0.010563:0.004088:0.005188:0.011061:0.009172:0.008259:0.016041:0.005105:0.010687:0.005105:0.010417:0.008965:0.005188:0.006018:0.010272:0.008218:0.005188:0.010065:0.005852:0.005229:0.004773:0.004792:0.005852:0.008840:0.005188:0.009857:0.005644:0.005188:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.005188:0.008985:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.003036:0.003735
mouse models. Nat. Rev. Cancer 15, 311–316 (2015).:@0.184412:0.654764:0.588153:0.654764:0.588153:0.636244:0.184412:0.636244:0.015896:0.009836:0.010376:0.007159:0.008218:0.003735:0.015896:0.010251:0.010293:0.008135:0.004773:0.006973:0.004088:0.003735:0.014130:0.008010:0.005852:0.004088:0.003735:0.012451:0.008487:0.007367:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
106. Heo, E. J. :@0.147059:0.675343:0.256710:0.675343:0.256710:0.656822:0.147059:0.656822:0.009483:0.009483:0.009483:0.004088:0.004814:0.014734:0.008280:0.009338:0.004088:0.003922:0.010998:0.004088:0.003922:0.005105:0.004088:0.003735
et al.:@0.256873:0.675343:0.292192:0.675343:0.292192:0.656631:0.256873:0.656631:0.007346:0.005727:0.004005:0.009048:0.004607:0.004586
 Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclini-:@0.292187:0.675343:0.882353:0.675343:0.882353:0.656822:0.292187:0.656822:0.003922:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.014754:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.003922:0.012555:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.003922:0.017245:0.010251:0.010293:0.008135:0.004773:0.006973:0.003922:0.009857:0.005644:0.003922:0.010459:0.010065:0.004794:0.006016:0.010274:0.008135:0.004773:0.005269:0.008550:0.004773:0.003922:0.015356:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003922:0.013613:0.008259:0.010544:0.008176:0.008218:0.007097:0.003922:0.005478:0.009857:0.007097:0.003922:0.010832:0.006765:0.008280:0.007969:0.004773:0.005105:0.010687:0.005032:0.006848
cal Studies. Cancer Res. Treat. 49, 915–926 (2017).:@0.184412:0.695922:0.567983:0.695922:0.567983:0.677401:0.184412:0.677401:0.008280:0.008550:0.004773:0.003735:0.008902:0.005603:0.010314:0.010355:0.005043:0.008218:0.006973:0.004088:0.003735:0.013611:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.012451:0.008218:0.006973:0.004088:0.003735:0.010210:0.006765:0.008446:0.008010:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
107. Liu, J. F. :@0.147059:0.716500:0.245110:0.716500:0.245110:0.697980:0.147059:0.697980:0.009483:0.009483:0.009483:0.004088:0.004814:0.010666:0.004794:0.010127:0.004088:0.003050:0.005105:0.004088:0.003050:0.007906:0.004088:0.003735
et al.:@0.244415:0.716500:0.278842:0.716500:0.278842:0.697789:0.244415:0.697789:0.007346:0.005727:0.003113:0.009048:0.004607:0.004586
 Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovari-:@0.278843:0.716500:0.882353:0.716500:0.882353:0.697980:0.278843:0.697980:0.003050:0.010998:0.006827:0.005956:0.008280:0.009917:0.004773:0.005105:0.006869:0.010417:0.015896:0.008218:0.010355:0.005852:0.003050:0.009857:0.005644:0.003050:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.014754:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.003050:0.009919:0.010376:0.015896:0.009857:0.007097:0.003050:0.012555:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.003050:0.017245:0.010251:0.010293:0.008135:0.004773:0.006973:0.003050:0.009857:0.005644:0.003050:0.010459:0.010065:0.004794:0.006018:0.010272:0.008135:0.004773:0.005269:0.008550:0.004773:0.003050:0.015356:0.008944:0.008259:0.007097:0.005078:0.006848
an Cancer for Preclinical Evaluation of Novel Therapeutics. Clin. Cancer Res. 23, 1263–1273 :@0.184412:0.737079:0.886078:0.737079:0.886078:0.718558:0.184412:0.718558:0.008259:0.010687:0.003113:0.013611:0.008259:0.010542:0.008176:0.008218:0.007097:0.003113:0.005478:0.009857:0.007097:0.003113:0.010832:0.006765:0.008280:0.007969:0.004773:0.005105:0.010687:0.005043:0.008280:0.008548:0.004773:0.003113:0.010729:0.008944:0.008550:0.004462:0.010542:0.008010:0.005852:0.005043:0.009857:0.010687:0.003113:0.009857:0.005644:0.003113:0.014111:0.009878:0.008757:0.008135:0.004773:0.003113:0.010428:0.010282:0.008218:0.007180:0.008010:0.010457:0.008301:0.010065:0.005852:0.005043:0.008176:0.006973:0.004088:0.003113:0.013403:0.004773:0.005105:0.010687:0.004088:0.003113:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003113:0.012451:0.008218:0.006973:0.004088:0.003113:0.009483:0.009483:0.004088:0.003113:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735
(2017).:@0.184412:0.757658:0.239051:0.757658:0.239051:0.739137:0.184412:0.739137:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
108. Bankert, R. B. :@0.147059:0.778237:0.295308:0.778237:0.295308:0.759716:0.147059:0.759716:0.009483:0.009483:0.009483:0.004088:0.004814:0.011704:0.008259:0.010791:0.009338:0.008218:0.007242:0.005852:0.004088:0.005043:0.012451:0.004088:0.005043:0.010957:0.004088:0.003735
et al.:@0.296638:0.778237:0.333119:0.778237:0.333119:0.759525:0.296638:0.759525:0.007346:0.005727:0.005167:0.009048:0.004607:0.004586
 Humanized mouse model of ovarian cancer recapitulates patient solid :@0.333114:0.778237:0.886016:0.778237:0.886016:0.759716:0.333114:0.759716:0.005043:0.014402:0.010376:0.015979:0.008259:0.010687:0.005105:0.008031:0.008280:0.010355:0.005043:0.015896:0.009836:0.010376:0.007159:0.008218:0.005043:0.015896:0.010251:0.010293:0.008135:0.004773:0.005043:0.009857:0.005644:0.005043:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.005043:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.005043:0.006765:0.008280:0.008278:0.008012:0.010065:0.004792:0.005603:0.010500:0.004939:0.008010:0.005644:0.008218:0.006973:0.005043:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.005043:0.007157:0.009942:0.004773:0.005041:0.010355:0.003735
tumor progression, ascites formation, and metastasis. PLoS One 6, e24420 (2011).:@0.184412:0.798815:0.806273:0.798815:0.806273:0.780294:0.184412:0.780294:0.005603:0.010376:0.015896:0.009857:0.007097:0.003735:0.010065:0.006765:0.010044:0.008965:0.006765:0.008218:0.006848:0.006910:0.005043:0.009857:0.010687:0.004088:0.003735:0.008446:0.007159:0.008176:0.004794:0.005644:0.008218:0.006973:0.003735:0.005476:0.009857:0.007097:0.015979:0.008010:0.005852:0.005043:0.009857:0.010687:0.004088:0.003735:0.008259:0.010542:0.010355:0.003735:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008446:0.006910:0.005105:0.006973:0.004088:0.003735:0.010604:0.010749:0.010044:0.009193:0.003735:0.014815:0.010544:0.008218:0.003735:0.009483:0.004088:0.003735:0.008218:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
109. Ricci, F. :@0.147059:0.819394:0.245938:0.819394:0.245938:0.800873:0.147059:0.800873:0.009483:0.009483:0.009483:0.004088:0.004814:0.012264:0.005043:0.008176:0.008176:0.004856:0.004088:0.003196:0.007904:0.004088:0.003735
et al.:@0.245382:0.819394:0.279955:0.819394:0.279955:0.800682:0.245382:0.800682:0.007346:0.005727:0.003258:0.009048:0.004607:0.004586
 Patient-derived ovarian tumor xenografts recapitulate human clinicopathology :@0.279954:0.819394:0.886129:0.819394:0.886129:0.800873:0.279954:0.800873:0.003196:0.010376:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.003185:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003196:0.005603:0.010376:0.015896:0.009857:0.007097:0.003196:0.008985:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.006973:0.003196:0.006765:0.008280:0.008280:0.008010:0.010065:0.004794:0.005603:0.010500:0.004939:0.008010:0.005644:0.008218:0.003185:0.010085:0.010376:0.015981:0.008259:0.010687:0.003196:0.007969:0.004773:0.005105:0.010687:0.005041:0.008176:0.009836:0.010334:0.008010:0.006018:0.010272:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735
and genetic alterations. Cancer Res. 74, 6980–6990 (2014).:@0.184412:0.839973:0.630984:0.839973:0.630984:0.821452:0.184412:0.821452:0.008259:0.010542:0.010355:0.003735:0.008778:0.008218:0.010542:0.008301:0.005852:0.005043:0.008176:0.003735:0.008550:0.004462:0.005644:0.008218:0.007180:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004088:0.003735:0.013611:0.008259:0.010544:0.008176:0.008218:0.007097:0.003735:0.012449:0.008218:0.006973:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
110. Topp, M. D. :@0.147059:0.860551:0.282110:0.860551:0.282110:0.842031:0.147059:0.842031:0.009483:0.009483:0.009483:0.004088:0.004814:0.009878:0.009836:0.010044:0.009546:0.004088:0.005416:0.017826:0.004088:0.005416:0.013738:0.004088:0.003735
et al.:@0.283811:0.860551:0.320666:0.860551:0.320666:0.841839:0.283811:0.841839:0.007346:0.005727:0.005541:0.009048:0.004607:0.004586
 Molecular correlates of platinum response in human high-grade serous :@0.320669:0.860551:0.886020:0.860551:0.886020:0.842031:0.320669:0.842031:0.005416:0.017245:0.009940:0.004711:0.008280:0.008278:0.010500:0.004939:0.008259:0.007097:0.005416:0.008176:0.009857:0.007097:0.006765:0.008135:0.004939:0.008010:0.005644:0.008218:0.006973:0.005416:0.009857:0.005644:0.005416:0.010148:0.004939:0.008010:0.005852:0.005105:0.010355:0.010376:0.016041:0.005416:0.006765:0.008218:0.006827:0.010459:0.009857:0.010563:0.007159:0.008218:0.005416:0.005105:0.010687:0.005416:0.010085:0.010376:0.015979:0.008259:0.010687:0.005416:0.010417:0.005105:0.009025:0.010417:0.006848:0.008965:0.007180:0.008446:0.010293:0.008218:0.005416:0.007157:0.008218:0.006765:0.009836:0.010376:0.006973:0.003735
ovarian cancer patient-derived xenografts. Mol. Oncol. 8, 656–668 (2014).:@0.184412:0.881130:0.750057:0.881130:0.750057:0.862609:0.184412:0.862609:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003735:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005041:0.008757:0.008280:0.010355:0.003735:0.008985:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.006973:0.004088:0.003735:0.017245:0.009940:0.004524:0.004088:0.003735:0.014817:0.010542:0.008176:0.009940:0.004524:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
111. George, E. :@0.147059:0.901709:0.267024:0.901709:0.267024:0.883188:0.147059:0.883188:0.009483:0.009483:0.009483:0.004088:0.004814:0.014381:0.008280:0.009857:0.006931:0.008778:0.007948:0.004088:0.003528:0.010998:0.004088:0.003735
et al.:@0.266833:0.901709:0.301758:0.901709:0.301758:0.882997:0.266833:0.882997:0.007346:0.005727:0.003611:0.009048:0.004607:0.004586
 A patient-derived-xenograft platform to study BRCA-deficient ovarian can-:@0.301761:0.901709:0.882353:0.901709:0.882353:0.883188:0.301761:0.883188:0.003528:0.013572:0.003528:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006848:0.010293:0.008218:0.007097:0.005043:0.008757:0.008280:0.010355:0.006848:0.008983:0.008218:0.010542:0.010044:0.008965:0.007180:0.008259:0.005634:0.005634:0.003528:0.010148:0.004939:0.008010:0.005852:0.005478:0.009857:0.007097:0.016041:0.003528:0.005644:0.010044:0.003528:0.006827:0.005603:0.010314:0.010293:0.008840:0.003528:0.011330:0.012098:0.013343:0.012368:0.006848:0.010293:0.008218:0.005167:0.005105:0.008176:0.005043:0.008218:0.010355:0.005852:0.003528:0.009878:0.008944:0.008259:0.007097:0.005271:0.008259:0.010687:0.003528:0.008280:0.008259:0.010754:0.006848